Ampio Pharmaceuticals reports additional Ampion data


Ampio Pharmaceuticals (AMPE) is out with more data from SPRING (see initial read-out from August) which shows Ampion achieved "significant results [on] secondary end points."

Reduction in pain versus saline was significant across the entire 12-week period.

A single injection produced "a clinically and statistically significant reduction in pain, with an estimated difference from control at the study endpoint of -0.25 on the WOMAC A scale." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs